Intertek — Stability Studies for Biopharmaceuticals
Timely and accurate evaluation of identity, strength, quality, purity and potency are key to successfully managing stability and release programs.
Timely and accurate evaluation of identity, strength, quality, purity and potency are key to successfully managing stability and release programs. With pharmaceutical stability storage capabilities in UK and Ireland, integrated with GMP analytical capabilities, Intertek scientists can design, initiate and conduct all aspects of your stability and batch release studies with specialist capabilities for biopharmaceuticals. Intertek stability studies for protein therapeutics, for example, can involve a range of technologies including; peptide fingerprinting / sequencing by LC-MS/MS, SDS-PAGE, IEF, amino acid analysis, CE, glycan analysis and more.
Intertek will be exhibiting at ICSE, Madrid in Oct 2009. Please Visit stand 8BIO40 to find out more
www.intertek.com/pharmaceutical
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
